Company Overview - Exelixis is a cancer-focused commercial company dedicated to improving the standard of care in cancer treatment for patients [1] - The company has a leading molecule in kidney cancer called CABOMETYX (cabozantinib), supported by strong data and a robust commercial platform [1] Recent Developments - The company launched a new indication for NET (neuroendocrine tumors) at the end of Q1, with the official launch occurring in Q2 [2] - Exelixis aims to expand beyond CABOMETYX by building a pipeline of franchise molecules, leveraging learnings from CABOMETYX over the past decade [2] - The next molecule in development is zanzolitinib, which is currently in various pivotal trials, alongside a deep pipeline of both small molecules [2]